News

The study showed that a three-month course of treatment with antibiotics could decrease the recurrence of cardiovascular events in patients without periodontitis, an infection of the gingiva or

The overall goal of the trial is to find the most appropriate dose that will result in efficacy with minimal side effects that are typically seen with other

Under the terms of the agreement, Cara received an upfront payment and will be eligible to receive pre-determined clinical and regulatory milestone payments. Cara is also eligible to

Orphan drug status may be granted to drugs that treat rare life-threatening diseases that affect less than 200,000 persons in the US. Such designation provides a company with

The study was published in the New England Journal of Medicine along with results of a similar study of GlaxoSmithKline’s rotavirus vaccine that was shown to reduce severe

Alfimeprase is currently in phase III development and has been shown in clinical studies to provide rapid clot dissolution with a well tolerated safety profile. Under the terms

Milnacipran is the first of a new class of agents known as norepinephrine serotonin reuptake inhibitors, or NSRIs, which exerts its effect by preferentially inhibiting the reuptake of

Innovive will develop the candidate NS-187 for the treatment of chronic myelogenous leukemia (CML) and anticipates commencing phase I trials this year. NS-187 is a dual Bcr-Abl and

The phase II trial is a randomized dose ranging study that will evaluate the efficacy and safety of the CNTF implant and will be conducted at the National